Dorzolamide: A Review
Authors:
- 1 January 1997
- journal article
- review article
- Published by Taylor & Francis in Seminars in Ophthalmology
- Vol. 12 (3) , 119-126
Abstract
Major advances in pharmacological research have led to the introduction of four new and potent topical ocular hypotensive agents within the past few years. The federal government requires stringent premarket testing to prove efficacy and safety. These safety and efficacy studies are performed on a finite number of patients over a limited period of time. After a drug has come to market, however, many more patients are exposed to it. Subtle idiosyncrasies of new agents and unanticipated side effects become apparent. As clinicians, we must recognize these events and use them to help guide us with our patient management. Dorzolamide (Trusopt, Merck and Co., Inc., West Point, PA), the first topical carbonic anhydrase inhibitor, has been clinically available for nearly 2 years. Much clinical data have been published about dorzolamide since it was first released. A brief review of the physiology of carbonic anhydrase inhibitors and the history of the development of the topical preparations will precede the discussion of the clinical use of dorzolamide.Keywords
This publication has 42 references indexed in Scilit:
- Distribution and function of carbonic anhydrase (CA) isozymes in the human eye. Relevance for the design of topical CA inhibitorsExperimental Eye Research, 1992
- Relations among IOP reduction, ocular disposition and pharmacology of the carbonic anhydrase inhibitor ethoxzolamideExperimental Eye Research, 1992
- Localization of carbonic anhydrase IV in a specific capillary bed of the human eye.Proceedings of the National Academy of Sciences, 1991
- Carbonic anhydrase: General perspective and advances in glaucoma researchDrug Development Research, 1987
- Failure of Acetazolamide to Decrease Intraocular Pressure in Patients with Carbonic Anhydrase II DeficiencyAmerican Journal of Ophthalmology, 1985
- Properties of Membrane‐bound Carbonic Anhydrasea,bAnnals of the New York Academy of Sciences, 1984
- The transcorneal permeability of sulfonamide carbonic anhydrase inhibitors and their effect on aqueous humor secretionExperimental Eye Research, 1983
- Relations Between Structure and Biological Activity of SulfonamidesAnnual Review of Pharmacology and Toxicology, 1976
- Effect of a Carbonic Anhydrase Inhibitor (Diamox) on Intra-Ocular Pressure of Rabbits and CatsBritish Journal of Ophthalmology, 1955
- Local Application of DiamoxAmerican Journal of Ophthalmology, 1955